

Product Name : Siguazodan

Synonyms : SKF 94836

Cat No. : M26446

CAS Number : 115344-47-3

Molecular Formula : C₁₄H₁₆N₆O

Formula Weight : 284.3

Chemical Name : —

Description : Siguazodan is an effective, selective, orally active phosphodiesterase III (PDE-III) inhibitor with an IC₅₀ of 117 nM. Siguazodan inhibited phenylephrine induced 5-HT release with an IC₅₀ value of 4.2 μM. Siguazodan can increase cAMP accumulation in intact platelets, with EC₅₀ of 18.88 μM. (In Vitro): Siguazodan increases cAMP accumulation in intact platelets with an EC₅₀ of 18.88 μM. Siguazodan also inhibits phenylephrine-induced 5-HT release with an IC₅₀ value of 4.2 μM. In platelet-rich plasma (PRP), Siguazodan inhibits U46619-induced aggregation more potently than that induced by adenosine 5'-diphosphate (ADP), and collagen. Treatment of the PRP with Aspirin has no effect on the potency of Siguazodan. In washed platelets, Siguazodan increases cyclic AMP levels and reduces cytoplasmic free calcium. ADP decreases the ability of Siguazodan to raise cyclic AMP and this may explain its lower potency in inhibiting responses to ADP. (In Vivo): Siguazodan has positive inotropic and vasodilating actions in various laboratory animals and is orally active with a long duration of action in conscious dogs.

Pathway : Angiogenesis

Target : PDE

Receptor : GABA

Solubility : —

SMILES : CN(C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)CC1C

Storage : (-20°C)

Stability : ≥ 2 years

Reference :

1.White WF, et al. Isoguvacine binding, uptake, and release: relation to the GABA system. J Neurochem. 1983 Jun;40(6):1701-8.